Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even after brief drug exposure, researchers reported.
A systematic review and meta-analysis of 18 randomized clinical trials comparing PARP inhibitors to placebo control in adults revealed more than double the risk for MDS and AML (Peto odds ratio [OR] 2.63, 95% CI 1.13-6.14, P=0.026) with PARP inhibitors, reported Joachim Alexandre, MD, of Caen University Hospital, France, and colleagues.